PMID- 10942398
OWN - NLM
STAT- MEDLINE
DCOM- 20000907
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 96
IP  - 4
DP  - 2000 Aug 15
TI  - High incidence of chromosome 13 deletion in multiple myeloma detected by 
      multiprobe interphase FISH.
PG  - 1505-11
AB  - Multiple myeloma (MM) is a hypoproliferative malignancy yielding informative 
      karyotypes in no more than 30% of newly diagnosed cases. Although cytogenetic and 
      molecular deletion of chromosome 13 is associated with poor prognosis, a MM tumor 
      suppressor gene (TSG) has not been identified. To localize a minimal deleted 
      region of chromosome 13, clonotypic plasma cells from 50 consecutive patients 
      with MM were subjected to interphase fluorescence in situ hybridization (FISH) 
      analysis using a panel of 11 probes spanning the entire long arm of chromosome 
      13. Whereas chromosome 13 abnormalities were absent in plasma cells from 25 
      normal donors, 86% of patients with MM demonstrated such aberrations. 
      Heterogeneity, both in deletion frequency and extent, was confirmed by 
      simultaneous FISH with 2 chromosome 13 probes. Deletion hot spots were noted at 
      D13S272 (70%) and D13S31 (64%), 2 unlinked loci at 13q14. Homozygous deletions at 
      these loci occurred in 12% (simultaneously in 8%) of the cases. Molecular 
      deletions were found in all 14 patients with morphologic deletions, in 21 of 24 
      with uninformative karyotypes, and 8 of 12 patients with karyotype abnormalities 
      lacking chromosome 13 deletion. Homozygous deletion of any marker was noted in 4% 
      with low and in 36% with higher plasma cell labeling index greater than 0. 4% (P 
      =.01). The absence of increasing deletion incidence and extent with therapy 
      duration suggests that the observed lesions are not induced by treatment. The 
      high incidence and extent of chromosome 13 deletions require the correlation of 
      specific deletion(s) with poor prognosis. These analyses will provide valuable 
      guidance toward cloning of an MM-TSG. (Blood. 2000;96:1505-1511)
FAU - Shaughnessy, J
AU  - Shaughnessy J
AD  - Myeloma and Transplantation Research Center, Division of Biometry, University of 
      Arkansas for Medical Sciences and Arkansas Cancer Research Center, Little Rock, 
      AR 72205, USA.
FAU - Tian, E
AU  - Tian E
FAU - Sawyer, J
AU  - Sawyer J
FAU - Bumm, K
AU  - Bumm K
FAU - Landes, R
AU  - Landes R
FAU - Badros, A
AU  - Badros A
FAU - Morris, C
AU  - Morris C
FAU - Tricot, G
AU  - Tricot G
FAU - Epstein, J
AU  - Epstein J
FAU - Barlogie, B
AU  - Barlogie B
LA  - eng
GR  - CA55819/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 13
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Karyotyping
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics
EDAT- 2000/08/15 11:00
MHDA- 2000/09/09 11:01
CRDT- 2000/08/15 11:00
PHST- 2000/08/15 11:00 [pubmed]
PHST- 2000/09/09 11:01 [medline]
PHST- 2000/08/15 11:00 [entrez]
AID - S0006-4971(20)71970-1 [pii]
PST - ppublish
SO  - Blood. 2000 Aug 15;96(4):1505-11.